Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies Akira I. HidaYasuaki SagaraYasuyo Ohi Preclinical study Open access 03 June 2016 Pages: 1 - 9
Proliferation assessment in breast carcinomas using digital image analysis based on virtual Ki67/cytokeratin double staining Rasmus RøgeRikke Riber-HansenMogens Vyberg Preclinical study 09 June 2016 Pages: 11 - 19
Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression Yanhong ZhangAdam L. LissCelina G. Kleer Preclinical study 11 June 2016 Pages: 21 - 28
Transcriptomic profiling of curcumin-treated human breast stem cells identifies a role for stearoyl-coa desaturase in breast cancer prevention Justin A. ColacinoSean P. McDermottLaura S. Rozek Preclinical study 15 June 2016 Pages: 29 - 41
Aberrant nocturnal cortisol and disease progression in women with breast cancer Jamie M. ZeitzerBita NourianiDavid Spiegel Preclinical study 17 June 2016 Pages: 43 - 50
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK) K. Matter-WalstraT. RuhstallerK. J. Dedes Clinical trial 08 June 2016 Pages: 51 - 57
Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients Alexander HeinPaul GassSara Y. Brucker Clinical trial 09 June 2016 Pages: 59 - 65
Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer Banu K. ArunYun GongNour Sneige Clinical trial 10 June 2016 Pages: 67 - 77
A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer Martha HickeyJennifer L. MarinoSwee Wong Clinical trial 15 June 2016 Pages: 79 - 90
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study L. M. SmythN. M. IyengarC. T. Dang Clinical Trial 15 June 2016 Pages: 91 - 97
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients Sasagu KurozumiMary PadillaHiroaki Nitta Clinical trial Open access 18 June 2016 Pages: 99 - 111
Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians Tulay Koru-SengulAna M. SantanderMarta Torroella-Kouri Epidemiology 09 June 2016 Pages: 113 - 126
A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL) Alfred I. NeugutGrace Clarke HillyerDawn L. Hershman Epidemiology 10 June 2016 Pages: 127 - 138
Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ Shi-Yi WangJessica B. LongCary P. Gross Epidemiology 10 June 2016 Pages: 139 - 148
Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses’ Health Study and Nurses’ Health Study II Kelly A. HirkoRenée T. FortnerA. Heather Eliassen Epidemiology 13 June 2016 Pages: 149 - 155
Measured adolescent body mass index and adult breast cancer in a cohort of 951,480 women Lital Keinan-BokerHagai LevineJeremy D. Kark Epidemiology 15 June 2016 Pages: 157 - 167
The recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases Hanna DillekåsRomano DemicheliOddbjørn Straume Epidemiology Open access 15 June 2016 Pages: 169 - 178
Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study Shusma C. DoebarEsther C. van den BroekCarolien H. M. van Deurzen Epidemiology Open access 18 June 2016 Pages: 179 - 187
Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer Shruti R. TiwariPrasun MishraAlberto J. Montero Brief Report 20 June 2016 Pages: 189 - 193
Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung Brennan McCullarManjari PandeyMichael G. Martin Brief Report 21 June 2016 Pages: 195 - 202